GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Gross Margin %

Novo Nordisk A/S (Novo Nordisk A/S) Gross Margin %

: 84.80% (As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Novo Nordisk A/S's Gross Profit for the three months ended in Dec. 2023 was $8,171 Mil. Novo Nordisk A/S's Revenue for the three months ended in Dec. 2023 was $9,636 Mil. Therefore, Novo Nordisk A/S's Gross Margin % for the quarter that ended in Dec. 2023 was 84.80%.


The historical rank and industry rank for Novo Nordisk A/S's Gross Margin % or its related term are showing as below:

NVO' s Gross Margin % Range Over the Past 10 Years
Min: 83.2   Med: 84.07   Max: 85
Current: 84.6


During the past 13 years, the highest Gross Margin % of Novo Nordisk A/S was 85.00%. The lowest was 83.20%. And the median was 84.07%.

NVO's Gross Margin % is ranked better than
78.78% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs NVO: 84.60

Novo Nordisk A/S had a gross margin of 84.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Novo Nordisk A/S was 0.10% per year.


Novo Nordisk A/S Gross Margin % Historical Data

The historical data trend for Novo Nordisk A/S's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.54 83.51 83.20 83.92 84.60

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.82 84.67 85.53 83.46 84.80

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Gross Margin % falls into.



Novo Nordisk A/S Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Novo Nordisk A/S's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=28749.3 / 33982.121
=(Revenue - Cost of Goods Sold) / Revenue
=(33982.121 - 5232.779) / 33982.121
=84.60 %

Novo Nordisk A/S's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=8171.3 / 9636.42
=(Revenue - Cost of Goods Sold) / Revenue
=(9636.42 - 1465.149) / 9636.42
=84.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Novo Nordisk A/S  (NYSE:NVO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Novo Nordisk A/S had a gross margin of 84.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Novo Nordisk A/S Gross Margin % Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.